Haemonetics Corp Mass Stock Price, News & Analysis

Haemonetics Corporation (NYSE: HAE) has officially launched operations at its new manufacturing Center of Excellence in Clinton, PA, covering 200,000 square feet. This facility enhances production capabilities for critical disposables and consumables across its Plasma and Hospital sectors. The site utilizes advanced technology and environmentally-friendly features, showcasing Haemonetics' commitment to operational excellence. With over 30 years in the Pittsburgh area, the company aims to improve patient outcomes while meeting growing demand.

Haemonetics Corporation (NYSE: HAE) will host its Investor Day on June 29, 2022, in Boston, starting at 10:00 AM EDT. This hybrid event allows for in-person attendance for capital markets professionals, while others can participate via a webcast. Attendees can engage with product demonstrations before the presentations. The Company aims to update stakeholders on strategies, market leadership in plasma and hospital sectors, and plans for financial growth through fiscal 2026. A replay and presentation materials will be available post-event.

Haemonetics Corporation (NYSE: HAE) has made its fourth quarter fiscal 2022 financial results available online, following the period ending April 2, 2022. A conference call will be held on May 10, 2022, at 8:00 a.m. EDT to discuss these results. Investors can access the earnings release, analytical tables, and supplemental information on the Investor Relations website. The earnings call will also be available for replay for one year after the event.

Haemonetics Corporation (NYSE: HAE) will host an Investor Day on June 29, 2022, at 10:00 AM EDT in Boston. The event aims to share insights on the Company’s long-term strategic plans, key initiatives, and financial outlook. It will be hybrid, allowing in-person attendance and a simultaneous webcast for remote participants. Registration is required via the Company's Investor Relations website. A replay and presentation materials will be available post-event on Haemonetics' website.

Haemonetics Corporation (NYSE: HAE) will publish its fourth quarter and fiscal year 2022 financial results on May 10, 2022, at 6:00 am EDT. An investor conference call for discussing these results will be held at 8:00 am EDT on the same day. Investors can access the call by dialing (877) 848-8880 for U.S. and Canada or (716) 335-9512 internationally, with Conference ID 5347317. A live webcast will also be available through Haemonetics' investor relations website, with a replay accessible for one year post-call.

Haemonetics Corporation (NYSE: HAE) announced the appointment of James C. D'Arecca as Executive Vice President and Chief Financial Officer, effective April 11, 2022. D'Arecca succeeds William P. Burke, who will remain in an advisory role until June 30, 2022. D'Arecca brings nearly 30 years of experience in finance leadership from companies like TherapeuticsMD and Allergan. His role will include overseeing treasury, tax, and financial planning, critical for Haemonetics' growth objectives. The appointment aims to strengthen the financial strategy and enhance stakeholder value.

Haemonetics Corporation (NYSE: HAE) announced that CEO Chris Simon will engage in a fireside chat with investors at the Raymond James 43rd Annual Institutional Investors Conference on March 7, 2022, at 9:50 a.m. ET. Interested individuals can access a live webcast through Haemonetics' Investor Relations website, and a replay will be available 12 hours post-event for a year. Haemonetics focuses on innovative healthcare solutions to enhance patient care and reduce costs, particularly in blood and plasma collection, surgical operations, and transfusion services.

Haemonetics Corporation (NYSE: HAE) announced its third quarter fiscal 2022 financial results, concluding on January 1, 2022. The details are accessible on its Investor Relations website. A conference call will take place on February 8, 2022, at 8:00 a.m. EST to discuss these results, with a live webcast and replay available for a year. Haemonetics specializes in innovative medical products and solutions aimed at enhancing patient care and reducing healthcare costs across blood and plasma collection, surgical suites, and hospital transfusion services.

Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2022 financial results on February 8, 2022, at 6:00 am EST. A conference call will be held at 8:00 am EST the same day, where executives will discuss the results and respond to questions. Investors can access the call via a toll-free number or participate through a live webcast on the company's investor relations website. A replay will be available for one year from the call's conclusion.